Datasets:

nzindoc

/

dataset-multiple-myeloma

like 0

Median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Comparison of the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The impact of patient characteristics on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The role of genetic factors in the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The influence of previous treatments on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The correlation between the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The role of supportive care in improving the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).

The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Median PFS for Placebo+Bortezomib+Dexamethasone (Vd)?

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Placebo+Bortezomib+Dexamethasone (Vd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Comparison of the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The impact of patient characteristics on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The role of genetic factors in the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The influence of previous treatments on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The correlation between the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The role of supportive care in improving the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)}

Median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Comparison of the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The impact of patient characteristics on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The role of genetic factors in the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The influence of previous treatments on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The effect of dosage and administration frequency on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The correlation between the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The impact of side effects and adverse reactions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The role of supportive care in improving the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The influence of disease stage at the start of treatment on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The effect of concurrent health conditions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).

The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Median PFS for Lenalidomide+Dexamethasone (Rd)?

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Lenalidomide+Dexamethasone (Rd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) ^{[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)}

Median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Comparison of the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The correlation between the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Median PFS for Lenalidomide+Dexamethasone (Rd)?

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Lenalidomide+Dexamethasone (Rd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)}

Median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)?

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Comparison of the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The impact of patient characteristics on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The role of genetic factors in the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The influence of previous treatments on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The effect of dosage and administration frequency on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The correlation between the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The impact of side effects and adverse reactions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The role of supportive care in improving the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The influence of disease stage at the start of treatment on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The effect of concurrent health conditions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).

The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)?

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Comparison of the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The impact of patient characteristics on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The role of genetic factors in the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The influence of previous treatments on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The effect of dosage and administration frequency on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The correlation between the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The impact of side effects and adverse reactions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The role of supportive care in improving the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The influence of disease stage at the start of treatment on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

The effect of concurrent health conditions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)}

Median PFS for Carfilzomib+Dexamethasone (Kd)?

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Carfilzomib+Dexamethasone (Kd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd).

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd). ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Median PFS for Bortezomib+Dexamethasone (Vd)?

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Bortezomib+Dexamethasone (Vd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}